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ABSTRACT
Background
Despite guidelines establishing the need to perform comprehensive paediatric drug
development programs, pivotal trials in children with epilepsy have been completed mostly
in Phase IV as a postapproval replication of adult data. However, it has been shown that the
treatment response in children can differ from that in adults. It has not been investigated
whether differences in drug effect between adults and children might occur in the treatment of
drug-resistant partial epilepsy, although such differences may have a substantial impact on the
design and results of paediatric randomised controlled trials (RCTs).
Methods and Findings
Three electronic databases were searched for RCTs investigating any antiepileptic drug (AED)
in the add-on treatment of drug-resistant partial epilepsy in both children and adults. The
treatment effect was compared between the two age groups using the ratio of the relative risk
(RR) of the 50% responder rate between active AEDs treatment and placebo groups, as well as
meta-regression. Differences in the response to placebo and to active treatment were searched
using logistic regression. A comparable approach was used for analysing secondary endpoints,
including seizure-free rate, total and adverse events-related withdrawal rates, and withdrawal
rate for seizure aggravation. Five AEDs were evaluated in both adults and children with drug-
resistant partial epilepsy in 32 RCTs. The treatment effect was significantly lower in children
than in adults (RR ratio: 0.67 [95% confidence interval (CI) 0.51–0.89]; p ¼ 0.02 by meta-
regression). This difference was related to an age-dependent variation in the response to
placebo, with a higher rate in children than in adults (19% versus 9.9%, p , 0.001), whereas no
significant difference was observed in the response to active treatment (37.2% versus 30.4%, p
¼ 0.364). The relative risk of the total withdrawal rate was also significantly lower in children
than in adults (RR ratio: 0.65 [95% CI 0.43–0.98], p ¼ 0.004 by metaregression), due to higher
withdrawal rate for seizure aggravation in children (5.6%) than in adults (0.7%) receiving
placebo (p , 0.001). Finally, there was no significant difference in the seizure-free rate between
adult and paediatric studies.
Conclusions
Children with drug-resistant partial epilepsy receiving placebo in double-blind RCTs
demonstrated significantly greater 50% responder rate than adults, probably reflecting
increased placebo and regression to the mean effects. Paediatric clinical trial designs should
account for these age-dependent variations of the response to placebo to reduce the risk of an
underestimated sample size that could result in falsely negative trials.
The Editors’ Summary of this article follows the references.
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Epilepsy is a common disorder in children that often
requires antiepileptic drug (AED) treatment for many years
[1]. However, most AEDs have inadequate paediatric use
information [2]. Indeed, AEDs are evaluated primarily in
adult patients [3], and only a few randomised controlled trials
(RCTs) have been performed in paediatric population [1].
Furthermore, despite reviews and guidelines establishing the
importance of comprehensive drug development programs in
children [2,4], most pivotal paediatric trials have been
completed in Phase IV as a postapproval replication of adult
data. Formulations, target doses, and expected effect size—
which determines trial design and sample size—have been
largely extrapolated from data collected in adult studies.
Overall, the typical practice has been to extend the use of
AEDs approved for adult epilepsy to children [5].
It has been shown that unpredictable differences may exist
in drug metabolism and treatment response between children
and adults [4,6]. For instance, the clearance of modern AEDs
was found to be 20% to 170% higher in children than in
adults [7]. Trial design could be affected as well—reluctance
to recruit children with epilepsy into AEDs trials [8] might
result in the selection of more severe epilepsy in paediatric
than in adult RCTs. Furthermore, it has been suggested that
the size of the placebo effect may be greater than usually
expected in children with developmental disabilities [9] or
migraine [10–12].
Whether age differences might exist in the treatment of
drug-resistant partial epilepsy has never been investigated,
despite the possibility that they may have an important
impact on the design of paediatric trials. Speciﬁcally, a
greater placebo effect in children than in adults would
narrow the expected effect size of AED treatment in the
former population, and it could lead to falsely negative RCT
outcomes if the sample size is directly extrapolated from data
collected in adult studies. To test this issue we performed a
meta-analysis that compared AED efﬁcacy in paediatric and
adult RCTs.
Materials and Methods
Literature Search
See Text S1 for the review protocol and Text S2 for the
QUOROM checklist.
Three electronic databases (MEDLINE, EMBASE, and the
Cochrane Library) were searched from 1960 to 30 June 2007,
for RCTs investigating any AED in the add-on treatment of
drug-resistant partial epilepsy. A detailed search strategy is
provided in Text S3. We searched for any additional studies
(i) in the clinical trials registries ISRCTN (http://isrctn.org/),
Current Controlled Trials (http://www.controlled-trials.com/
mrct/), ClinicalTrials.gov (http://www.ClinicalTrials.gov/), and
the Centre for Reviews and Dissemination (University of
York, UK) Database of Abstracts of Reviews of Effectiveness
(DARE; http://www.crd.york.ac.uk/); (ii) in the abstracts of the
International Epilepsy Congress and the European Epilepsy
Congress, the annual meeting of the American Epileptic
Society (http://www.aesnet.org/), and the annual meeting of
the American Academy of Neurology (http://www.aan.com/);
(iii) in the references of all identiﬁed publications, including
previous relevant meta-analyses and narrative reviews; and
(iv) by contacting the pharmaceutical companies involved in
the development of modern licensed AEDs (including
gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pre-
gabalin, tiagabine, topiramate, vigabatrin, and zonisamide) to
exclude the possibility of relevant unpublished RCTs. No
language restrictions were applied.
Study Selection
The following criteria were used to select relevant RCTs:
double-blind placebo-controlled design; patients with drug-
resistant partial epilepsy with or without secondary general-
ization; adequate method of concealment of randomization
(e.g., allocation of sequentially numbered sealed packages of
medication, sealed opaque envelopes, telephone random-
ization) minimum baseline period 4 wk; minimum treatment
phase 8 wk; efﬁcacy as a primary endpoint; available data
regarding the 50% responder rate; and number of with-
drawals due to loss to follow up unlikely to affect the
robustness of the results. Only drugs that have been evaluated
in both adult and paediatric populations were included in
further analyses.
We focused on drug-resistant partial epilepsy for several
reasons. AEDs are ﬁrst evaluated in patients with this
condition before being tested in those with newly diagnosed
epilepsy and refractory generalised epilepsies [3]. Further-
more, in RCTs in patients with newly diagnosed epilepsy, for
ethical reasons AEDs are usually not compared to placebo but
to another active treatment, whereas the nine RCTs
performed in patients with refractory generalized epilepsy
included a mixed population of children and adults without
providing detailed results by age groups [13–21].
Drug-resistant partial epilepsy is deﬁned by the Interna-
tional League Against Epilepsy (ILAE; http://www.ilae.org/) as
an epileptic disorder characterised by: (i) seizures whose
initial signs and symptoms indicate, or are consistent with,
initial involvement of only part of one hemisphere [22] and
(ii) persistent seizures during a minimum of 2 y despite
treatment with trials of at least two different AEDs used at the
therapeutic level [23–26]. However, the inclusion criteria used
in RCTs are more stringent and usually require that the
patient had failed three or more AEDs, while the actual
average number of failed AEDs reported in those trials is
often eight or more [23].
Data Abstraction
The following information were extracted and entered
independently into databases by two investigators (SR and
PR): (i) study design—number of treatment arms, masking
description, randomisation description, baseline description,
titration period, and treatment period duration; (ii) patients’
characteristics—age, type of seizures (partial or generalized),
number of patients per arm, percentage of male sex, number
of concomitant AEDs, and median seizure frequency during
the baseline period (28 d); (iii) intervention—type and mean
dose; (iv) outcomes— primary and secondary outcomes of the
study, number of 50% responder patients per arm in an
intention to treat (ITT) analysis on the whole treatment
period, number of withdrawals per arm, and number of
patients excluded from the published analysis with reasons.
For crossover studies, the ﬁrst treatment period was treated
as a parallel trial (i.e., only data from the ﬁrst treatment
period were used), and we discarded the second treatment
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slightly from published ﬁgures, the tabular data were used. If
some information about study design or seizure outcomes
were not reported, the authors were contacted to obtain the
required information.
Trials were ﬁnally classiﬁed as paediatric or adult trials
according to the age of the patients. Paediatric trials were
deﬁned by a maximum age of patients , 18 y [27]. Adult trials
included a majority of patients   18 y, but some also included
a few adolescents (age . 12 y [27]).
The results of the two resulting databases were compared
and disagreements resolved by consensus. The quality of the
reports was assessed by the Jadad score [28].
Endpoints
The primary endpoint was the 50% responder rate (50% or
greater reduction in seizure frequency during the treatment
period as compared to baseline). All doses evaluated in trials
were included. A secondary analysis was restricted to
comparable doses between paediatric and adult studies.
Dosages were considered ‘‘comparable’’ when the difference
between paediatric and adult doses (expressed in mg/kg) was
, 35%. In adult trials, where the target dose was never
adjusted to body weight, we calculated the mean dose (mg/kg)
by dividing the target dose (mg) by the average body weight of
the population. When this latter information was not
provided, we used the average body weight observed in the
other trials included in our study (i.e., 70 kg).
Secondary endpoints included the seizure-free rate (no
seizure during the entire treatment period); the total with-
drawal rate, which included all dropouts occurring during the
treatment period; the adverse events withdrawal rate, which
included only dropouts related to side effects; and the
withdrawal rate for seizure aggravation.
The 50% responder and withdrawal rates for active AEDs
treatment and placebo arms were extracted in an ITT analysis
on the whole treatment period.
The seizure-free rate for active AEDs treatment and
placebo arms was extracted in a modiﬁed ITT analysis. Only
patients who remained seizure free during the entire treat-
ment period were considered to achieve seizure-free out-
come. Indeed, the alternative use of standard ITT analysis,
based on the principle of last observation carried forward,
has been considered inappropriate for analysing seizure-free
outcome [29].
Statistical Methods
To evaluate efﬁcacy of AEDs, we performed a meta-analysis
that compared the 50% responder rate in active AEDs
treatment group with the one observed in placebo group, and
used the logarithm of relative risk method. This analysis was
done separately in paediatric and in adult populations.
Treatment effect and heterogeneity tests were performed,
and a p-value of , 0.05 from a treatment effect test and of ,
0.10 from a heterogeneity test (Cochrane Q-test) were
considered statistically signiﬁcant. We also used the I
2 statistic
and its 95% CI, which is independent of the number of
studies and quantiﬁes heterogeneity on a scale of 0% to
100%. Very large heterogeneity between studies is usually
denoted by I
2 values of 75% or more [30]. In the absence of a
clear explanation for heterogeneity, a random-effect model
for the relative risk (RR) was planned.
To compare efﬁcacy of AEDs in children and in adults, we
calculated for each drug the ratio of the RR of the 50%
responder rate observed in paediatric and in adult trials. To
further assess the robustness of this ratio, we used a meta-
regression approach with the log odds ratio as a dependent
variable and a restricted maximum likelihood method for the
estimation. Subanalyses were planned a priori to determine
whether doses of AEDs or methodological quality was
responsible for signiﬁcant heterogeneity. The same statistical
methods were used to analyse the seizure-free rate, the total
withdrawal rate, the adverse events withdrawal rate, and the
withdrawal rate for seizure aggravation.
Meta-analyses were performed using the software EasyMA
[31,32] and their results are presented graphically, including
RRs and corresponding 95% CIs, as well as RR ratio for the
comparison between adult and children.
The baseline risk of the primary and secondary endpoints
was compared between adult and paediatric trials using
logistic regression, with a level of signiﬁcance at p , 0.05.
Results
The initial search for RCTs investigating any AED in the
add-on treatment of drug-resistant partial epilepsy yielded
2,122 articles. A review of the abstracts and exclusion of
irrelevant and duplicate articles yielded 109 articles (Figure
1). Of the 109 articles examined, we excluded 25 open-label
trials or trials with inappropriate blinding methods, seven
studies with inappropriate randomization, two studies with a
response conditional design, two studies with a period of
treatment phase shorter than 8 wk, one monotherapy study,
ten studies with inappropriate baseline, ﬁve review articles,
ﬁve studies for which we were unable to determine the 50%
responder rate, and two duplicate studies, leaving 50
potentially eligible studies (Figure 1). Among these 50 studies,
we excluded 18 that investigated AEDs that have not been
evaluated in paediatric populations (Figure 1). Two trials
were only published in abstract [33,34]. However, the main
data regarding the study design and the 50% responder rate
were directly available in these abstracts, and missing
information could be retrieved in the corresponding system-
atic review performed by the Cochrane Collaboration Group
[35,36]. No other unpublished RCTs fulﬁlling our criteria was
notiﬁed by pharmaceutical companies.
Five drugs—gabapentin (GBP), levetiracetam (LEV), lamo-
trigine (LTG), oxcarbazepine (OXC), and topiramate (TPM)—
were evaluated in 32 RCTs fulﬁlling our inclusion criteria,
with at least one trial in children and another one in adults
for each AED. Five RCTs included children; the other 27
included adults. The main characteristics and results of these
trials are given in Tables 1 and 2, as well as in Figure 2, while
their detailed characteristics are presented in Text S4. The
mean age of patients was 10 y in paediatric trials and 33 y in
adult trials. In children, it ranged from 2 to 17 y. However,
information about baseline characteristics and seizure out-
come in different age subgroups (i.e., , 6, 6–12, and . 12 y)
was never provided. Study designs were similar between
paediatric and adult trials. All paediatric trials were
performed with parallel groups. In adults, there were nine
crossover trials and 18 trials with parallel groups. The mean
duration of the baseline was nonsigniﬁcantly shorter in
children than in adults (7.6 and 9.5 wk, respectively; p¼0.067).
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paediatric and adult trials. With the exception of LTG trials,
in which the paediatric dose was similar to the adult one, the
mean dose studied was different in children and adults trials.
It was 57% higher in the paediatric GBP trial than in adults,
100% higher in the paediatric LEV trial than in adults, and
60% higher in the paediatric OXC study than in adults. By
contrast, for TPM, the mean dose studied was 50% lower in
paediatric trials than in adults. We did not observe differ-
ences in the baseline patient characteristics, suggesting
substantial clinical heterogeneity between adult and paedi-
atric trials, although some data were missing in some trials
(Table 1). The sex ratio, seizure types, baseline seizure
frequency, and number of background AEDs were similar in
both populations. An average of 85% of adult patients and
82% of children suffered from complex partial seizures,
whereas 41% of adults and 47% of children suffered from
secondarily generalised partial seizures (p¼0.44). The median
seizure frequency per month was 11.8 in children and 10.1 in
adults (p ¼ 0.69). When these ﬁgures were compared for each
drug, separately, comparable median seizure frequency were
found in children and adults for GBP, LTG, LEV, and OXC.
By contrast, in TPM trials, children had a median seizure
frequency twice that of adults (21 and 10.5 per month,
respectively). The aetiology of the disease was rarely speciﬁed,
and could not be compared between age groups. However, it
should be stressed that 40% of the children included in the
LTG paediatric trial were diagnosed as suffering from
idiopathic epilepsy. This form of epilepsy was not reported
in other trials, and is often considered an exclusion criterion
in RCTs performed in adult patients with drug-resistant
partial epilepsy.
Figure 1. Flow Diagrams of Trials
doi:10.1371/journal.pmed.0050166.g001
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Age and Placebo Response in AED TrialsPrimary Endpoint: Comparison of the 50% Responder Rate
Indirect comparison of the RR of the 50% responder rate
in adults and children showed lower values in children (1.91
[95% CI 1.54–2.37]) than in adults (2.90 [2.47–3.41]), with
conﬁdence intervals that did not overlap (Figures 2 and 3A).
When we tested this issue further in a meta-analysis that
calculated the RR ratio of the 50% responder rate between
adults and children for each of the ﬁve drugs, we conﬁrmed a
signiﬁcant difference (0.67 [95% CI 0.51–0.89], p ¼ 0.007)
pointing to lower values in children (Figure 3A). No
signiﬁcant heterogeneity was observed between drugs in this
analysis (Figures 2 and 3A). These ﬁndings were further
conﬁrmed by the meta-regression, demonstrating a signiﬁ-
cant relation between the age of patients and the treatment
effect (p ¼ 0.02).
The above ﬁndings were found to primarily reﬂect differ-
ences in the response of the two populations to placebo.
Indeed, logistic regression showed that the mean 50%
responder rate in patients receiving placebo was signiﬁcantly
higher in children (19% 6 2.3%) than in adults (9.9% 6
4.6%) (p , 0.001), whereas no signiﬁcant difference was
observed in the response to AEDs between these two
populations (37.2% 6 9.4% in children versus 30.4% 6
13.9% in adults, p ¼ 0.364) (Figure 3B). The 1.9 times greater
50% responder rate observed in children receiving placebo as
compared to adult was a consistent ﬁnding across all AEDs,
Figure 2. Proportion of 50% Responders in Each Trial
I
2, point estimates of Higgins I
2 with confidence interval; p Het, value of the heterogeneity test; p TE, value of the treatment effect test.
doi:10.1371/journal.pmed.0050166.g002
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Age and Placebo Response in AED Trialsincluding LTG (1.7 for OXC and GBP, 1.8 for TPM, 1.9 for
LEV, and 2.0 for LTG).
All above results remained valid when the same analyses
were restricted to comparable doses between paediatric and
adult trials (Figure S1). The RR ratio of the 50% responder
rate between adults and children was 0.63 (95% CI 0.47–0.84)
(p ¼ 0.002). These ﬁndings were conﬁrmed by the meta-
regression, demonstrating a signiﬁcant relation between the
age of patients and the treatment effect (p ¼ 0.02). Similarly,
the 50% responder rate in patients receiving placebo
remained signiﬁcantly higher in children (19% 6 2.3%) than
in adults (10.1% 6 4.1%) (p , 0.001, Figure S1B).
Secondary Endpoints
Seizure-free rate (Figure 4). The seizure-free rate was
provided in only 15 of the 32 trials, including 11 of the 27
adults trials and four of the ﬁve paediatric trials (Table 2).
Furthermore, the published data did not allow to calculate
the number of seizure-free patients in the modiﬁed ITT
population (see methods) in seven trials. However, these data
could be retrieved for three of these seven trials from a
recently published meta-analysis that focused on seizure-free
outcome [29]. Overall, the seizure-free rate in the modiﬁed
ITT population was available for four AEDs (GBP, LEV, OXC,
and TPM) in seven adult and four children trials (Table 2).
The RR of seizure-free rate was 4.19 (95% CI 1.45–12.14) in
adult trials and 5.00 (1.52–16.42) in paediatric trials. There
was no signiﬁcant difference between adult and paediatric
studies (RR ratio 1.42 [95% CI 0.23–8.77], p ¼ 0.704; p ¼ 0.68
by meta-regression). In addition, the seizure-free rate in
treatment and placebo arms were similar in both populations,
with 2.8% of adults and 4.5% of children receiving AEDs (p¼
Figure 3. Analysis of the 50% Responder Rate Including All Dosages
(A) RR of 50% responder rate in adult and paediatric trials and comparison of RR of 50% responder rate in children and adults.
(B) Mean 50% responder rate with placebo and with AED in adult and paediatric trials. * p , 0.001 (logistic regression).
I
2, point estimates of Higgins I
2 with confidence interval; k, total number of trials; n, total number of patients; p Het, value of the heterogeneity test; p
TE, value of the treatment effect test.
doi:10.1371/journal.pmed.0050166.g003
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Age and Placebo Response in AED Trials0.256), and 0.4% of adults and 0.6% of children receiving
placebo (p ¼ 0.607) achieving seizure freedom during the
entire treatment period.
Withdrawal rates (Figure 5). In adults, both the total and
adverse events withdrawal rates were signiﬁcantly more
frequent in treatment than in placebo arms. Indeed, the RR
of the withdrawal rates for any reason and for adverse events
were respectively 1.57 (95% CI 1.33–1.86) and 2.49 (1.90–3.28)
(Figures 5A and 5B). By contrast, in children, neither the total
nor the adverse events withdrawal rates differed between
treatment and placebo arms (RR 0.89 [95% CI 0.64–1.22] for
total withdrawal rate and of 1.24 [0.70–2.20] for adverse
events withdrawal rate). When comparing the RRs of the total
withdrawal rate between the two populations, there was no
overlap between the conﬁdence intervals observed in
children (0.64–1.22) and adults (1.33–1.86). Accordingly,
meta-analysis of the RR ratio demonstrated signiﬁcant
differences between the two populations for the total
withdrawal rate, with a ratio of 0.65 (95% CI 0.43–0.98, p ¼
0.037) pointing to lower RR values in paediatric trials (Figure
5A), a ﬁnding conﬁrmed by the meta-regression (p ¼ 0.004).
When analysing the above differences, we found a non-
signiﬁcant higher total withdrawal rate in children receiving
placebo (13.3%) than in adults (7%) (p ¼ 0.08, Figure 5D),
whereas no difference was observed between the two
populations in the active treatment arm (13.4% in adults
and 11.8% in children, p ¼ 0.775).
The meta-analysis of the RR ratio for the adverse events
withdrawal rate also demonstrated signiﬁcantly lower values
in children than in adult RCTs, with a ratio of 0.51 (95% CI
0.26–0.98, p¼0.045). However, this ﬁnding was not conﬁrmed
by the meta-regression (p ¼ 0.08).
There was no difference in the RR of withdrawal rate for
seizure aggravation between adults (0.74 [95% CI 0.28–1.98], p
¼ 0.55) and children (1.24 [0.70–2.20], p ¼ 0.13), as further
demonstrated by the RR ratio (1.24 [0.33–4.62], p ¼ 0.754,
Figure 5C) and the meta-regression (p ¼ 0.605). However,
logistic regression showed that children receiving placebo
dropped out for an aggravation of seizures (5.6%) more
frequently than adults (0.7%) (p , 0.001, Figure 5D).
Figure 4. Analysis of the Seizure-Free Rate
(A) RR of seizure-free rate in adult and paediatric trials and comparison of RR of seizure-free rate in children and adults.
(B) Mean seizure-free rate with placebo and with AED in adult and paediatric trials.
I
2, point estimates of Higgins I
2 with confidence interval; k, total number of trials; n, total number of patients; p Het, value of the heterogeneity test; p
TE, value of the treatment effect test.
doi:10.1371/journal.pmed.0050166.g004
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Age and Placebo Response in AED TrialsFigure 5. Analysis of the Withdrawal Rates
(A) RR of withdrawal for any reason in adult and paediatric trials and comparison of RR of the total withdrawal rate in children and adults.
(B) Comparison of RR of the adverse events withdrawal rate in children and adults.
(C) Comparison of RR of the withdrawal rate related to seizure aggravation in children and adults.
(D) Mean withdrawal rate for either any reasons, adverse events or seizure aggravation with placebo and with AED in adult and paediatric trials. * p ,
0.001 (logistic regression).
I
2, point estimates of Higgins I
2 with confidence interval; k, total number of trials; n, total number of patients; p Het, value of the heterogeneity test; p
TE, value of the treatment effect test.
doi:10.1371/journal.pmed.0050166.g005
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in loss to follow-up and consent withdrawal (Table 2).
Discussion
In this meta-analysis, we found that the RR of the 50%
responder rate for active AEDs over placebo, one of the main
measurements of AED efﬁcacy in drug-resistant partial
epilepsy, was signiﬁcantly lower in paediatric trials than in
adult ones. This difference was primarily related to a 2-fold
higher placebo responder rate in children than in adults.
Such a difference, if ignored, could well result in an
underestimation of the placebo response and type II errors
in paediatric RCTs.
Study Limitations
Only ﬁve RCTs fulﬁlling our selection criteria were
performed in children, representing one trial per AED. Thus,
each paediatric trial might have had an important weight in
the meta-analysis. However, the very consistent ﬁndings
observed among four of the ﬁve selected AEDs strongly
suggest that our main result did not depend on any single
paediatric trial, but rather on the consistency of the majority
of RCTs in children.
Our study focused on refractory partial epilepsy, for which
AEDs are usually tested during Phases II and III before
further evaluation is considered in newly diagnosed epilepsy
and refractory generalised epileptic syndromes. Diagnosis of
partial seizures was always based on the association of ictal
signs and symptoms suggesting an underlying focal neuronal
discharge and consistent neurophysiological ﬁndings on a
recent electroencephalogram. According to these inclusion
criteria, it is very unlikely that the patients included in the
selected RCTs could have been misdiagnosed.
However, differences in the type of partial epilepsy might
account for the opposite trend observed for LTG as
compared to the four other AEDs, with higher RR of 50%
responder rate in children than in adults. Idiopathic partial
epilepsies, which are typically benign conditions, are ex-
cluded in Phase III RCTs performed in adult patients with
drug-resistant partial epilepsy, and are also unlikely to meet
the inclusion criteria of RCTs performed in children with
refractory partial seizures. Accordingly, there was no in-
dication that patients with idiopathic epilepsy were included
in the RCTs selected for this meta-analysis, with the
exception of the LTG paediatric trial in which 40% of
patients were classiﬁed as having idiopathic epilepsy [37].
This rate could partly account for the 2-fold higher
responder rate observed in children receiving LTG compared
to adults (42% versus 20%), a difference not observed for the
four other AEDs (GBP, 21% versus 19%; OXC, 40% versus
39%; TPM, 39% versus 44%; LEV, 45% versus 37%).
More generally, we cannot exclude the possibility that
clinical heterogeneity between adults and children as well as
between trials in the same age group might have interfered
with our results. It has recently been suggested that the
statistical tests available for evaluating heterogeneity between
studies (i.e., Cochran Q and Higgins I
2) may suffer some
limitations [38,39]. Although the I
2 did not demonstrate
signiﬁcant heterogeneity in our meta-analysis, its upper 95%
CI ranged between 50% and 75% in some analyses, and more
rarely exceeded the 75% threshold. Comparable conﬁdence
intervals of I
2 have been reported in 83% of the Cochrane
meta-analyses [39], but no recommendation on the manage-
ment of this limitation has yet been published.
The reluctance to recruit children with epilepsy into AEDs
trials [8] might have resulted in the selection of more severe
epilepsy in paediatric than in adult RCTs. In fact, the baseline
median monthly seizure frequency was comparable in trials
with children and adults for the entire study as well as for
four of the ﬁve tested AEDs (GBP, LTG, LEV, and OXC).
Furthermore, the important issue of poor seizure count
reliability [40,41], which might differ between children and
adults, is also unlikely to explain a difference in the 50%
responder rate selectively to placebo.
Drug dosages differed between adult and paediatric trials,
partly reﬂecting the fact that the clearance of modern AEDs
is 20%–170% higher in children than in adults [7]. However,
our main ﬁndings remain unchanged when we reprocessed all
our analyses among a selection of RCTs and study arms that
resulted in comparable doses in the two age groups.
We used an ITT assessment that may be overly conserva-
tive. However, it must be stressed that the same method was
used in all the Cochrane systematic reviews of AEDs
[35,36,42–48], as well as in previously published meta-analyses
[49–51]. The major reason for preferring ITT rather than per-
protocol analysis is that the criteria used for deﬁning the
latter greatly vary between trials and AEDs.
Finally, whether the age-dependent variation of the
response to placebo observed in this study might apply to
generalized epilepsies remains to be determined.
Higher Response to Placebo in Children Than in Adults
The overall difference in the RR of being a 50% responder
between adult and paediatric trials was primarily related to
an age-dependent variation in the response to placebo.
Indeed, placebo 50% responder rate was 1.9 times higher in
children than in adults, in a very consistent way across all
AEDs, including LTG. It has been suggested that the response
to placebo may depend on the age of patients [9–12]. It
should be remembered, however, that the RCTs considered in
our meta-analysis did not include a patient group receiving
no intervention. Thus, we did not measure the placebo effect
per se but all nonpharmacological effects that include the
placebo effect, but also the Hawthorne effect, the regression
to the mean, and the clinical course of epilepsy.
The reasons underlying the higher response to placebo in
paediatric populations remains largely unknown and mostly
speculative. In placebo-controlled studies of antimigraine
agents, adolescents were more likely to believe that the
treatment received was an effective pain relieving medication
than were adults [12]. A placebo effect by proxy may also be
suggested in younger populations, since parents play an
important role in reporting the outcome of their affected
child [9]. The higher 50% responder rate observed in our
study in children compared to adults may also partly reﬂect a
regression to the mean effect. This regression to the mean
effect might be greater in paediatric than in adults RCTs due
to several factors, including the marked reluctance of parents
to enrol their affected child in placebo-controlled trials [5],
the trend observed in this meta-analysis toward shorter
baseline duration in paediatric than in adult RCTs, and the
possibility of greater short-term changes in seizure frequency
in children than in adults.
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responder rate observed between children and adults, the
RR of the seizure-free rate was found to be comparable in the
two populations. Seizure-free rates in placebo groups were
quite low in both children (0.6%) and adults (0.4%),
suggesting that this outcome is insensitive to nonpharmaco-
logical effects. However, the seizure-free rate was also low in
patients receiving AEDs (4.5% in children and 2.8% in
adults), accounting for the fact that this outcome failed to
show a signiﬁcant difference between active treatment and
placebo arms in the 11 series in which it was available. Thus,
the seizure-free rate, though representing a more clinically
relevant and less placebo-sensitive outcome than the 50%
responder rate, appears inappropriate for Phase III RCTs in
patients with drug-resistant partial epilepsy.
We observed a signiﬁcantly lower RR of the withdrawal rate
in children than in adults, primarily reﬂecting a greater
dropout rate from placebo arms in the former population
(13.3%) than in the latter (7%). This greater dropout rate in
placebo-treated children might have theoretically contrib-
uted to the increased 50% responder rate observed in the
same population. Indeed, according to the method of last
observation carried forward used in all the selected RCTs,
patients who withdraw early from the study because of
adverse events might be more likely to achieve a 50%
reduction in seizure frequency during the shorter time spent
in the trial. However, this possibility does not seem to apply
to our ﬁndings, since the greater withdrawal rate observed in
children receiving placebo was primarily due to more
frequent aggravation of seizures in these patients (5.6%)
than in adults allocated to placebo (0.7%).
Impacts on Future AEDs Trials in Paediatric Populations
The impact of our ﬁndings on future AED development
programs in children needs to be emphasized. Recent reviews
and guidelines have established that comprehensive drug
development is needed in paediatric populations, including
double-blind RCTs, but also have stressed the difﬁculties in
achieving this goal [2,4]. Both the United States and the
European Union have developed paediatric investigation
plans, including ﬁnancial incentives for pharmaceutical
companies to perform speciﬁc drug trials in children
[4,52,53]. These regulations aim at facilitating the develop-
ment and use of medicinal products in children and at
ensuring that medicinal products used to treat the paediatric
population are subject to ethical, high-quality research [52].
These regulations also establish that the above objectives
should be achieved without delaying the authorisation of
medicinal products for other age populations [27,52] and
without subjecting the paediatric population to unnecessary
clinical trials [52]. In that context, one can hardly afford the
risk of an underestimated sample size and related type II
error that would result in a falsely negative trial. In fact, two
of the ﬁve selected RCTs performed in children with drug-
resistant partial epilepsy failed to demonstrate a signiﬁcant
difference in the 50% responder rate between the active drug
(GBP and TPM) and placebo [54,55], whereas adults trials with
the same AEDs and comparable or slightly lower sample sizes
all demonstrated signiﬁcant differences in 50% responder
rate between active treatment and placebo [56–58]. It would
also be unethical to grossly overestimate the number of
children to be included in a double-blind, placebo-controlled
study, in order to ensure sufﬁcient statistical power. We thus
need to provide as much precise data as we can to optimally
design paediatric RCTs in drug-resistant partial epilepsy.
According to the results of this meta-analysis, we recommend
calculating statistical power for paediatric RCTs on the
premise of a 50% responder rate comparable to that
observed in adults for the active treatment group, and of
20% (or twice that observed in the adult RCTs for the same
AED) for placebo.
The value of add-on placebo-controlled RCTs in children
with drug-resistant partial epilepsy may also be in question.
Other trial designs such as the comparison of low and high
doses of the same drug [59] or response-conditional design
[60–63] have been proposed, but both have possible statistical
[8] or ethical issues [62]. Thus, it is likely that classic add-on
placebo-controlled RCTs will continue to be used for the
development of AEDs in the near future, and will beneﬁt
from more precise knowledge regarding the response to
placebo in the paediatric population.
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Age and Placebo Response in AED TrialsEditors’ Summary
Background. Whenever an adult is given a drug to treat a specific
condition, that drug will have been tested in ‘‘randomized controlled
trials’’ (RCTs). In RCTs, a drug’s effects are compared to those of another
drug for the same condition (or to a placebo, dummy drug) by giving
groups of adult patients the different treatments and measuring how
well each drug deals with the condition and whether it has any other
effects on the patients’ health. However, many drugs given to children
have only been tested in adults, the assumption being that children can
safely take the same drugs as adults provided the dose is scaled down.
This approach to treatment is generally taken in epilepsy, a common
brain disorder in children in which disruptions in the electrical activity of
part (partial epilepsy) or all (generalized epilepsy) of the brain cause
seizures. The symptoms of epilepsy depend on which part of the brain is
disrupted and can include abnormal sensations, loss of consciousness, or
convulsions. Most but not all patients can be successfully treated with
antiepileptic drugs, which reduce or stop the occurrence of seizures.
Why Was This Study Done? It is increasingly clear that children and
adults respond differently to many drugs, including antiepileptic drugs.
For example, children often break down drugs differently from adults, so
a safe dose for an adult may be fatal to a child even after scaling down
for body size, or it may be ineffective because of quicker clearance from
the child’s body. Consequently, regulatory bodies around the world now
require comprehensive drug development programs in children as well
as in adults. However, for pediatric trials to yield useful results, the
general differences in the treatment response between children and
adults must first be determined and then allowed for in the design of
pediatric RCTs. In this study, the researchers investigate whether there is
any evidence in published RCTs for age-dependent differences in the
response to antiepileptic drugs in drug-resistant partial epilepsy.
What Did the Researchers Do and Find? The researchers searched the
literature for reports of RCTs on the effects of antiepileptic drugs in the
add-on treatment of drug-resistant partial epilepsy in children and in
adults—that is, trials that compared the effects of giving an additional
antiepileptic drug with those of giving a placebo by asking what fraction
of patients given each treatment had a 50% reduction in seizure
frequency during the treatment period compared to a baseline period
(the ‘‘50% responder rate’’). This ‘‘systematic review’’ yielded 32 RCTs,
including five pediatric RCTs. The researchers then compared the
treatment effect (the ratio of the 50% responder rate in the treatment
arm to the placebo arm) in the two age groups using a statistical
approach called ‘‘meta-analysis’’ to pool the results of these studies. The
treatment effect, they report, was significantly lower in children than in
adults. Further analysis indicated that this difference was because more
children than adults responded to the placebo. Nearly 1 in 5 children had
a 50% reduction in seizure rate when given a placebo compared to only
1 in 10 adults. About a third of both children and adults had a 50%
reduction in seizure rate when given antiepileptic drugs.
What Do These Findings Mean? These findings, although limited by
the small number of pediatric trials done so far, suggest that children
with drug-resistant partial epilepsy respond more strongly in RCTs to
placebo than adults. Although additional studies need to be done to find
an explanation for this observation and to discover whether anything
similar occurs in other conditions, this difference between children and
adults should be taken into account in the design of future pediatric
trials on the effects of antiepileptic drugs, and possibly drugs for other
conditions. Specifically, to reduce the risk of false-negative results, this
finding suggests that it might be necessary to increase the size of future
pediatric trials to ensure that the trials have enough power to discover
effects of the drugs tested, if they exist.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050166.
  This study is further discussed in a PLoS Medicine Perspective by Terry
Klassen and colleagues
  The European Medicines Agency provides information about the
regulation of medicines for children in Europe
  The US Food and Drug Administration Office of Pediatric Therapeutics
provides similar information for the US
  The UK Medicines and Healthcare products Regulatory Agency also
provides information on why medicines need to be tested in children
  The MedlinePlus encyclopedia has a page on epilepsy (in English and
Spanish)
  The US National Institute for Neurological Disorders and Stroke and
the UK National Health Service Direct health encyclopedia both
provide information on epilepsy for patients (in several languages)
  Neuroscience for Kids is an educational Web site prepared by Eric
Chudler (University of Washington, Seattle, US) that includes informa-
tion on epilepsy and a list of links to epilepsy organizations (mainly in
English but some sections in other languages as well)
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